Exparel with Bubivacaine — Competitive Intelligence Brief

Exparel with Bubivacaine (Exparel with Bubivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (liposomal formulation). Area: Pain Management / Anesthesia.

marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels Pain Management / Anesthesia Small molecule

Target snapshot

Exparel with Bubivacaine (Exparel with Bubivacaine) — Maimonides Medical Center. Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthetic effect by slowly releasing bupivacaine from lipid vesicles at the injection site.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exparel with Bubivacaine TARGET	Exparel with Bubivacaine	Maimonides Medical Center	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Isobaric bupivacaine 0.5%	Isobaric bupivacaine 0.5%	Hospital Clínico Universitario de Valencia	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Naropeine (Ropivacaine)	Naropeine (Ropivacaine)	Nantes University Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
IV Lidocaine	IV Lidocaine	University of Washington	marketed	Local anesthetic / Antiarrhythmic agent (Class IB)	Voltage-gated sodium channels
Anesthesia (Lidocaine 15%)	Anesthesia (Lidocaine 15%)	Lumbini Medical College	marketed	Local anesthetic	Voltage-gated sodium channels
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (liposomal formulation) class)

1. Pacira Pharmaceuticals, Inc · 4 drugs in this class
2. Huazhong University of Science and Technology · 1 drug in this class
3. Maimonides Medical Center · 1 drug in this class
4. The Cleveland Clinic · 1 drug in this class
5. The Cooper Health System · 1 drug in this class
6. The University of Texas Health Science Center, Houston · 1 drug in this class
7. Tianjin Medical University General Hospital · 1 drug in this class
8. University of California, Davis · 1 drug in this class
9. Catherine Vandepitte, M.D. · 1 drug in this class
10. Wake Forest University Health Sciences · 1 drug in this class